HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

Migration, Crosslink

📖

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

active

wiki page Created: 2026-04-02T07:19:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-hif1a-protein

📖 Wiki Page

protein1867 wordssynced 2026-04-02

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

Overview

HIF-1α (Hypoxia-Inducible Factor 1-alpha) is the oxygen-sensitive subunit of the HIF-1 transcription factor heterodimer. It is the master regulator of cellular adaptation to low oxygen tension (hypoxia), controlling the expression of hundreds of genes involved in energy metabolism, angiogenesis, erythropoiesis, and cell survival [@semenza2012]. HIF-1α dimerizes with HIF-1β (ARNT) to form the active transcription factor, which binds to hypoxia-response elements (HREs) in the promoters of target genes. Under normoxic conditions, HIF-1α is continuously degraded via the VHL-dependent ubiquitin-proteasome pathway. Under hypoxia, degradation is inhibited, allowing HIF-1α to accumulate, translocate to the nucleus, and activate its transcriptional program [@wang1995].

...

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

Overview

HIF-1α (Hypoxia-Inducible Factor 1-alpha) is the oxygen-sensitive subunit of the HIF-1 transcription factor heterodimer. It is the master regulator of cellular adaptation to low oxygen tension (hypoxia), controlling the expression of hundreds of genes involved in energy metabolism, angiogenesis, erythropoiesis, and cell survival [@semenza2012]. HIF-1α dimerizes with HIF-1β (ARNT) to form the active transcription factor, which binds to hypoxia-response elements (HREs) in the promoters of target genes. Under normoxic conditions, HIF-1α is continuously degraded via the VHL-dependent ubiquitin-proteasome pathway. Under hypoxia, degradation is inhibited, allowing HIF-1α to accumulate, translocate to the nucleus, and activate its transcriptional program [@wang1995].

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">HIF-1α Protein</th></tr>
<tr><td>Protein Name</td><td>Hypoxia-Inducible Factor 1-Alpha</td></tr>
<tr><td>Gene</td><td>[HIF1A](/genes/hif1a)</td></tr>
<tr><td>UniProt ID</td><td>[Q16665](https://www.uniprot.org/uniprot/Q16665)</td></tr>
<tr><td>PDB IDs</td><td>1H2M, 4H6J</td></tr>
<tr><td>Molecular Weight</td><td>92.6 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus, Cytoplasm</td></tr>
<tr><td>Protein Family</td><td>bHLH-PAS transcription factor family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">586 edges</a></td>
</tr>
</table>
</div>

Structure

HIF-1α is a 826-amino acid protein with distinct structural domains:

bHLH domain (residues 1-70): Basic helix-loop-helix region required for DNA binding to the core sequence 5'-RCGTG-3' (HRE)

PAS-A domain (residues 80-160): Per-Arnt-Sim homology domain A — involved in heterodimerization

PAS-B domain (residues 230-330): Per-Arnt-Sim homology domain B — also contributes to dimerization

ODD domain (residues 400-600): Oxygen-dependent degradation domain — contains hydroxylation sites (Pro402, Pro564) regulated by PHD enzymes

N-TAD (residues 500-570): N-terminal transactivation domain — interacts with p300/CBP coactivators

C-TAD (residues 780-826): C-terminal transactivation domain — primary site of p300 recruitment

Heterodimerization with HIF-1β (ARNT) occurs via the PAS domains, creating a functional transcription factor complex that recruits the coactivator p300/CBP via the TAD domains.

Regulation

Oxygen-Dependent Regulation

The canonical regulation of HIF-1α is oxygen-dependent:

Normoxia: Under well-oxygenated conditions, prolyl hydroxylases (PHD1/EGLN2, PHD2/EGLN1, PHD3/EGLN3) hydroxylate specific proline residues (Pro402, Pro564) in the ODD domain [@semenza2012]

VHL recognition: Hydroxylated HIF-1α is recognized by the von Hippel-Lindau (VHL) tumor suppressor protein, which is part of an E3 ubiquitin ligase complex

Ubiquitination and degradation: polyubiquitination targets HIF-1α for proteasomal degradation, maintaining very low baseline levels

Hypoxia: Low O₂ inhibits PHD activity (PHDs require O₂ as a cosubstrate), preventing hydroxylation and VHL recognition. Unhydroxylated HIF-1α accumulates, translocates to the nucleus, and drives transcription

Additional Regulatory Mechanisms

Asparagine hydroxylation: Factor inhibiting HIF (FIH) hydroxylates Asn803 in the C-TAD under moderate hypoxia, blocking p300 recruitment
Post-translational modifications: Phosphorylation (by GSK3β, MAPK), acetylation (by p300), and SUMOylation modulate stability and activity
Transcriptional and translational control: HIF1A mRNA can be translationally upregulated under stress conditions
Feedback regulation: HIF-1 induces PHD2 and PHD3 expression, creating a negative feedback loop that tunes the hypoxic response

Normal Function

HIF-1α is the central mediator of the cellular adaptive response to hypoxia:

Metabolic Adaptation

Glycolysis upregulation: Induces GLUT1 (SLC2A1), hexokinases (HK1, HK2), phosphofructokinase (PFKL), and pyruvate dehydrogenase kinase 1 (PDK1), shifting energy production from oxidative phosphorylation to glycolysis
Angiogenesis: Induces VEGF (VEGFA) and VEGFR2 expression to promote new blood vessel formation
Erythropoiesis: Induces EPO (erythropoietin) to stimulate red blood cell production
Autophagy: Activates BNIP3 and other autophagy genes to promote cell survival under stress

Cell Survival Pathways

Anti-apoptotic genes: Induces BCL2, survivin (BIRC5), and erythropoietin for direct neuroprotective effects
DNA repair genes: Upregulates genes involved in base excision repair and homologous recombination
Stress response genes: Activates HO-1 (heme oxygenase 1) and other antioxidant response genes

Tissue-Specific Functions

Brain: Regulates cerebral blood flow, metabolic adaptation to ischemia, and neuroprotection
Retina: Critical for retinal vascularization and photoreceptor survival
Kidney: Central regulator of erythropoietin production
Heart: Cardioprotection during ischemic episodes

Role in Neurodegeneration

The role of HIF-1α in neurodegenerative diseases is complex and context-dependent, with both neuroprotective and detrimental effects documented [@cheng2021].

Alzheimer's Disease

In AD, HIF-1α plays a dual role:

Neuroprotective effects:

HIF-1α activation is a compensatory response to chronic cerebral hypoperfusion observed in AD [@correia2021]
VEGF induction promotes angiogenesis and may improve cerebral blood flow
Glycolytic shift helps neurons maintain ATP production despite mitochondrial dysfunction
Induction of amyloid-degrading enzymes (IDE, MMP9) may reduce Aβ burden
EPO and other HIF target genes provide direct neuroprotection

Detrimental effects:

Chronic HIF-1α activation may promote Aβ production via increased APP expression
Can contribute to neuroinflammation through VEGF-mediated blood-brain barrier disruption
May promote tau hyperphosphorylation through metabolic stress pathways

Postmortem AD brain studies show increased HIF-1α expression, particularly in neurons surrounding amyloid plaques, suggesting a sustained but insufficient adaptive response [@cheng2021].

Parkinson's Disease

In PD, HIF-1α provides neuroprotection to dopaminergic neurons [@wang2020]:

Ischemic preconditioning: Prior exposure to mild hypoxia via HIF-1α activation protects neurons against subsequent severe insults
Mitochondrial protection: HIF-1α helps neurons cope with mitochondrial Complex I deficiency common in PD
α-synuclein toxicity: HIF-1α activation can reduce α-synuclein aggregation and protect against dopaminergic neuronal death
Inflammatory modulation: Regulates microglial activation and neuroinflammatory responses

Stroke and Ischemia

HIF-1α is acutely protective in cerebral ischemia:

Ischemic preconditioning (IPC) induces HIF-1α and protects against subsequent stroke [@sharp2004]
HIF-1α target genes (EPO, VEGF, GLUT1, BDNF) promote neuronal survival and tissue perfusion
Pharmacologic HIF activation before stroke is neuroprotective in animal models
However, timing is critical — excessive late-phase HIF activation may worsen outcomes

ALS and Motor Neuron Disease

HIF-1α dysregulation is observed in SOD1 mouse models and human ALS tissue
Motor neurons are particularly vulnerable to hypoxic stress
Therapeutic targeting of HIF pathways is under investigation

Multiple Sclerosis

HIF-1α plays context-dependent roles in MS:

Myelin repair: HIF-1α promotes oligodendrocyte precursor differentiation
Blood-brain barrier: HIF-1α regulates BBB integrity
Autoimmunity: T cell HIF-1α affects cytokine production

Vascular Cognitive Impairment

Cerebral small vessel disease shares features with AD:

Chronic hypoperfusion: Reduced cerebral blood flow in VCID
White matter lesions: HIF-1α in demyelinating lesions
Therapeutic potential: HIF stabilization may improve outcomes

Traumatic Brain Injury

HIF-1α responds to acute brain injury:

Acute neuroprotection: Early HIF-1α activation is protective
Angiogenesis: Promotes revascularization
Long-term outcomes: Complex, timing-dependent effects

COVID-19 and the Brain

Emerging evidence links COVID-19 to neurological symptoms:

Hypoxia: Severe COVID-19 causes cerebral hypoxia
Cognitive impairment: "Long COVID" includes brain fog
HIF-1α: May mediate both protective and pathological responses

Molecular Mechanisms

HIF Target Gene Network

HIF-1α regulates hundreds of genes through hypoxia response elements (HREs, 5'-RCGTG-3'):

Metabolic Genes

| Gene | Function | Relevance to Neurodegeneration |
|------|----------|------------------------------|
| GLUT1 (SLC2A1) | Glucose transporter | Metabolic adaptation |
| HK1/HK2 | Hexokinases | Glycolysis |
| PDK1 | Pyruvate dehydrogenase kinase | Metabolic shift |
| LDHA | Lactate dehydrogenase | Glycolysis |

Angiogenesis Genes

| Gene | Function | Relevance to Neurodegeneration |
|------|----------|------------------------------|
| VEGFA | Vascular endothelial growth factor | Angiogenesis, also neurotoxic in excess |
| ANGPTL4 | Angiopoietin-like 4 | Permeability |
| PLIN2 | Perilipin 2 | Lipid metabolism |

Survival Genes

| Gene | Function | Relevance to Neurodegeneration |
|------|----------|------------------------------|
| EPO | Erythropoietin | Neuroprotection |
| BCL2 | Anti-apoptotic | Cell survival |
|survivin (BIRC5) | Inhibitor of apoptosis | Cell division |
| NQO1 | NADPH quinone dehydrogenase | Antioxidant |

Autophagy Genes

| Gene | Function | Relevance to Neurodegeneration |
|------|----------|------------------------------|
| BNIP3 | Pro-autophagic | Mitophagy |
| BNIP3L/NIX | Pro-autophagic | Mitophagy |
| MAP1LC3B | Microtubule-associated | Autophagosome |
| p62/SQSTM1 | Selective autophagy | Protein clearance |

Non-Hypoxic HIF Activation

HIF-1α can be activated without hypoxia:

Growth Factor Signaling

PI3K/AKT/mTOR pathway: AKT promotes HIF-1α translation
MAPK pathway: ERK1/2 enhances HIF-1α transcriptional activity
GSK3β: Paradoxically promotes degradation

Inflammatory Signaling

NF-κB: Cross-talk with HIF-1α transcription
TNF-α: Can stabilize HIF-1α
IL-1β: Synergistic activation

Metabolic Signaling

Succinate accumulation: Inhibits PHD, stabilizes HIF
Fumarate: Fumarate accumulation (FH mutations) stabilizes HIF
Reactive oxygen species: Can promote HIF activation

HIF Isoforms and Specificity

HIF-1α vs. HIF-2α (EPAS1)

| Feature | HIF-1α | HIF-2α (EPAS1) |
|---------|--------|----------------|
| Gene | HIF1A | EPAS1 |
| Expression | Ubiquitous | Endothelial cells, brain |
| Target genes | Overlapping but distinct | Some unique targets |
| Role in cancer | Promotes proliferation | Promotes tumor growth |
| Neuronal role | Acute response | Chronic hypoxia |

HIF-1β (ARNT)

Constitutively expressed
Shared subunit for HIF-1α and HIF-2α
Essential for dimerization
Not oxygen-regulated

Therapeutic Targeting

HIF Prolyl Hydroxylase Inhibitors (HIF-PHI)

These small molecules stabilize HIF-1α by inhibiting PHD enzymes, mimicking the hypoxic response:

| Drug | Target | Status | Notes |
|------|--------|--------|-------|
| Roxadustat (FG-4592) | PHD1/2/3 | Approved (ESA) | FDA-approved for anemia; CNS penetration being studied |
| Vadadustat (AKB-6548) | PHD1/2/3 | Approved (ESA) | Similar profile to roxadustat |
| Daprodustat (GSK1278863) | PHD1/2/3 | Approved (ESA) | Approved for anemia in CKD |
| FG-2216 | PHD | Preclinical | First-generation compound |

Neurodegeneration research:

Roxadustat and vadadustat show neuroprotective effects in mouse models of stroke, AD, and PD
Preconditioning effect: PHD inhibitors administered 24-48h before stroke reduce infarct volume
Clinical trials for neuroprotection are in early stages [@vangeel2020; @masson2019]

Gene Therapy Approaches

Viral delivery of HIF-1α or PHD shRNA to the brain
Exosomes loaded with HIF-1α mRNA for targeted delivery
Cell-permeable peptides stabilizing HIF-1α

Small Molecule Activators

DMOG (dimethyloxalylglycine): Pan-PHD inhibitor, widely used in research, not clinically available
CoCl₂: Chemical hypoxia mimetic, induces HIF-1α but toxic at high doses
Angiotensin II: Indirectly activates HIF-1α via AT1 receptor

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|----------------|----------------------|
| HIF-1β (ARNT) | Heterodimerization | Forms active transcription factor complex |
| VHL | E3 ligase binding | Normoxic degradation via ubiquitin-proteasome |
| PHD1/2/3 (EGLN1/2/3) | Prolyl hydroxylation | Oxygen-dependent regulation |
| FIH (HIF1AN) | Asparaginyl hydroxylation | Blocks p300 recruitment |
| p300/CBP | Coactivator recruitment | Transcriptional activation |
| HDAC1/2/3 | Deacetylase interaction | Modulates transcriptional activity |
| GSK3β | Phosphorylation | Promotes proteasomal degradation |
| PIN1 | Prolyl isomerization | Modulates stability and activity |

Research Directions

Temporal dynamics: Understanding when HIF-1α is protective vs. harmful in each disease stage

Cell type specificity: Neuronal vs. glial HIF-1α may have opposing effects

Combination therapy: HIF-PHI + conventional neuroprotective agents

Biomarker development: Imaging HIF-1α activation as a predictive biomarker

Novel PHD inhibitors: Next-generation compounds with improved CNS penetration

Pathway & Interaction Diagram

Interactive diagram showing HIF1A key relationships in the SciDEX knowledge graph (15 connections shown).

Mermaid diagram (expand to render)

References

[Semenza GL, Hypoxia-inducible factors in physiology and medicine (2012)](https://pubmed.ncbi.nlm.nih.gov/22304911/)

[Wang GL et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer (1995)](https://pubmed.ncbi.nlm.nih.gov/7539918/)

[Sharp FR et al., Hypoxic preconditioning: a central role for HIF-1 in neuroprotection (2004)](https://pubmed.ncbi.nlm.nih.gov/15545690/)

[Zhang H et al., HIF-1alpha and mitochondrial dysfunction (2008)](https://pubmed.ncbi.nlm.nih.gov/18046329/)

[Schito L, Semenza GL, HIF in cancer progression (2019)](https://pubmed.ncbi.nlm.nih.gov/31647581/)

[Peers C et al., HIF in neuronal survival and ischemic preconditioning (2015)](https://pubmed.ncbi.nlm.nih.gov/25708295/)

[Vangeel E et al., HIF prolyl hydroxylase inhibitors (2020)](https://pubmed.ncbi.nlm.nih.gov/31904376/)

[Cheng J et al., HIF-1alpha in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33418498/)

[Wang X et al., HIF-1alpha in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32871279/)

[Masson FR, Ratcliffe PJ, HIF-PHI in neurologic disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31786767/)

[Correia SC et al., HIF-1alpha and mitochondrial dysfunction in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/33895156/)

📖 View canonical wiki page →

Related Entities

HIF1APROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-hif1a-protein
kg_node_id	HIF1APROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-cf1455633436
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-hif1a-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

0

Incoming

16

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

Overview

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

Overview

Structure

Regulation

Oxygen-Dependent Regulation

Additional Regulatory Mechanisms

Normal Function

Metabolic Adaptation

Cell Survival Pathways

Tissue-Specific Functions

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Stroke and Ischemia

ALS and Motor Neuron Disease

Multiple Sclerosis

Vascular Cognitive Impairment

Traumatic Brain Injury

COVID-19 and the Brain

Molecular Mechanisms

HIF Target Gene Network

Metabolic Genes

Angiogenesis Genes

Survival Genes

Autophagy Genes

Non-Hypoxic HIF Activation

Growth Factor Signaling

Inflammatory Signaling

Metabolic Signaling

HIF Isoforms and Specificity

HIF-1α vs. HIF-2α (EPAS1)

HIF-1β (ARNT)

Therapeutic Targeting

HIF Prolyl Hydroxylase Inhibitors (HIF-PHI)

Gene Therapy Approaches

Small Molecule Activators

Protein Interactions

Research Directions

Pathway & Interaction Diagram

See Also

References

💬 Discussion